


## BDP FL-PEG5-propargyl

<b>Cat. No.:</b>	HY-141087
<b>CAS No.:</b>	2093197-93-2
<b>Molecular Formula:</b>	$C_{27}H_{38}B_3F_2N_3O_6^{2-}$
<b>Molecular Weight:</b>	571.04
<b>Target:</b>	PROTAC Linkers
<b>Pathway:</b>	PROTAC
<b>Storage:</b>	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (175.12 mM; ultrasonic and warming and heat to 60°C)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.7512 mL	8.7560 mL	17.5119 mL
	5 mM	0.3502 mL	1.7512 mL	3.5024 mL
	10 mM	0.1751 mL	0.8756 mL	1.7512 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

BDP FL-PEG5-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

PEGs

#### In Vitro

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA